Rationale:
Pulmonary hypertension (PH) has been described in patients treated with
leflunomide. Objectives: To assess the association between
leflunomide and PH. Methods: We identified incident cases of PH in patients treated with
leflunomide from the French PH Registry and through the pharmacoVIGIlAnce in
Pulmonary ArTerial Hypertension (VIGIAPATH) program between September 1999 to December 2019. PH etiology, clinical, functional, radiologic, and hemodynamic characteristics were reviewed at baseline and follow-up. A pharmacovigilance disproportionality analysis using the World Health Organization's global database was conducted. We then investigated the effect of
leflunomide on human pulmonary endothelial cells. Data are expressed as median (min-max). Results: Twenty-eight patients treated with
leflunomide before PH diagnosis was identified. A total of 21 (75%) had another risk factor for PH and 2 had two risk factors. The median time between
leflunomide initiation and PH diagnosis was 32 months (1-120). Right heart catheterization confirmed precapillary PH with a cardiac index of 2.37 L⋅min-1 ⋅m-2 (1.19-3.1) and elevated pulmonary vascular resistance at 9.63 Wood Units (3.6-22.1) without
nitric oxide reversibility. Five patients (17.9%) had no other risk factor for PH besides exposure to
leflunomide. No significant hemodynamic improvement was observed after
leflunomide withdrawal. The pharmacovigilance disproportionality analysis using the World Health Organization's database revealed a significant overrepresentation of
leflunomide among reported
pulmonary arterial hypertension-
adverse drug reactions. In vitro studies showed the dose-dependent toxicity of
leflunomide on human pulmonary endothelial cells. Conclusions: PH associated with
leflunomide is rare and usually associated with other risk factors. The pharmacovigilance analysis suggests an association reinforced by experimental data.